JP2014500862A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014500862A5 JP2014500862A5 JP2013536823A JP2013536823A JP2014500862A5 JP 2014500862 A5 JP2014500862 A5 JP 2014500862A5 JP 2013536823 A JP2013536823 A JP 2013536823A JP 2013536823 A JP2013536823 A JP 2013536823A JP 2014500862 A5 JP2014500862 A5 JP 2014500862A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- secad
- therapeutic agent
- cancer therapeutic
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40736710P | 2010-10-27 | 2010-10-27 | |
| US61/407,367 | 2010-10-27 | ||
| PCT/US2011/058076 WO2012058418A2 (en) | 2010-10-27 | 2011-10-27 | Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014500862A JP2014500862A (ja) | 2014-01-16 |
| JP2014500862A5 true JP2014500862A5 (enExample) | 2014-12-18 |
| JP6243737B2 JP6243737B2 (ja) | 2017-12-06 |
Family
ID=45994754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013536823A Active JP6243737B2 (ja) | 2010-10-27 | 2011-10-27 | Ｅ−カドヘリンの可溶性細胞外ドメインを標的とする組成物および癌治療のための関連方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20130287784A1 (enExample) |
| EP (1) | EP2632489B1 (enExample) |
| JP (1) | JP6243737B2 (enExample) |
| KR (1) | KR20140075639A (enExample) |
| CN (1) | CN103582494A (enExample) |
| AU (1) | AU2011319777B2 (enExample) |
| BR (1) | BR112013010535A2 (enExample) |
| CA (1) | CA2816358A1 (enExample) |
| ES (1) | ES2784385T3 (enExample) |
| MX (2) | MX357167B (enExample) |
| RU (1) | RU2013123792A (enExample) |
| SG (3) | SG10201604467PA (enExample) |
| WO (1) | WO2012058418A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9534058B2 (en) | 2012-02-08 | 2017-01-03 | Abbvie Stemcentrx Llc | Anti-CD324 monoclonal antibodies and uses thereof |
| CN104519899A (zh) * | 2012-03-15 | 2015-04-15 | 纽约州立大学研究基金会 | 包含e-钙粘蛋白的细胞外结构域的抑制剂的组合疗法 |
| US9411750B2 (en) * | 2012-07-30 | 2016-08-09 | International Business Machines Corporation | Efficient calibration of a low power parallel data communications channel |
| US9474034B1 (en) | 2015-11-30 | 2016-10-18 | International Business Machines Corporation | Power reduction in a parallel data communications interface using clock resynchronization |
| US10321351B2 (en) | 2017-03-02 | 2019-06-11 | Cable Television Laboratories, Inc. | System and method for grant assignment |
| JP2019511866A (ja) | 2016-03-10 | 2019-04-25 | ケーブル テレビジョン ラボラトリーズ，インク． | レイテンシ低減のためのシステム及び方法 |
| US10492104B2 (en) | 2016-03-10 | 2019-11-26 | Cable Television Laboratories, Inc. | Latency reduction in wireless service |
| US10738127B2 (en) | 2016-06-10 | 2020-08-11 | Veritas Biotecnologia Ltda | Monoclonal antibodies prevent cell surface protein shedding and block tumor growth |
| US10420085B2 (en) | 2016-10-07 | 2019-09-17 | Cable Television Laboratories, Inc. | System and method for grant assignment |
| US12225536B2 (en) | 2016-10-07 | 2025-02-11 | Cable Television Laboratories, Inc. | System and method for grant assignment |
| EP3791570B1 (en) | 2018-05-11 | 2026-04-29 | Axon Enterprise, Inc. | Systems and methods for cross-redaction |
| US20240317880A1 (en) * | 2020-01-10 | 2024-09-26 | Kling Biotherapeutics B.V. | Epithelial Cadherin-Specific Antibodies |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| KR940009084B1 (ko) | 1988-05-18 | 1994-09-29 | 체크 포인트 시스템스, 인코오퍼레이티드 | 자기 및 공명회로 검출용 안테나 시스템 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| AU662148B2 (en) | 1991-04-10 | 1995-08-24 | Scripps Research Institute, The | Heterodimeric receptor libraries using phagemids |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| US6093399A (en) | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
| WO1993017715A1 (en) | 1992-03-05 | 1993-09-16 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US6004555A (en) | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for the specific coagulation of vasculature |
| US5877289A (en) | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
| AU5669494A (en) * | 1992-11-17 | 1994-06-08 | Yale University | Human homolog of the e-cadherin gene and methods based thereon |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
| US6723320B2 (en) * | 1996-07-24 | 2004-04-20 | Gsf Forschungszentrum Fur Umwelt Und Geshundheit Gmbh | Mutations of E cadherin as a basis for the diagnosis and therapy of human malignant tumors |
| US6015557A (en) | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
| WO2002034880A2 (en) * | 2000-10-23 | 2002-05-02 | University Of Kansas | Cadherin peptides for drug delivery and inhibition of tumor metastasis/invasion |
| WO2002081655A2 (en) | 2001-03-28 | 2002-10-17 | Children's Medical Center Corporation | Fusion protein construct and method for inducing hiv-specific serum igg and secretory iga antibodies in-vivo |
| US6997863B2 (en) | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| US7074175B2 (en) | 2001-07-25 | 2006-07-11 | Erik Schroeder Handy | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| EP1592455A4 (en) | 2003-01-23 | 2006-06-28 | Univ Rochester | HERPES VIRUS amplicon PARTICLE |
| US8455249B2 (en) * | 2009-05-01 | 2013-06-04 | The University Of Tokyo | Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo |
-
2011
- 2011-10-27 KR KR1020137013383A patent/KR20140075639A/ko not_active Ceased
- 2011-10-27 CA CA2816358A patent/CA2816358A1/en not_active Abandoned
- 2011-10-27 EP EP11837082.4A patent/EP2632489B1/en active Active
- 2011-10-27 SG SG10201604467PA patent/SG10201604467PA/en unknown
- 2011-10-27 AU AU2011319777A patent/AU2011319777B2/en active Active
- 2011-10-27 SG SG2013032875A patent/SG189547A1/en unknown
- 2011-10-27 ES ES11837082T patent/ES2784385T3/es active Active
- 2011-10-27 CN CN201180063111.1A patent/CN103582494A/zh active Pending
- 2011-10-27 US US13/882,078 patent/US20130287784A1/en not_active Abandoned
- 2011-10-27 MX MX2013004790A patent/MX357167B/es active IP Right Grant
- 2011-10-27 RU RU2013123792/15A patent/RU2013123792A/ru not_active Application Discontinuation
- 2011-10-27 WO PCT/US2011/058076 patent/WO2012058418A2/en not_active Ceased
- 2011-10-27 SG SG10202100921YA patent/SG10202100921YA/en unknown
- 2011-10-27 BR BR112013010535A patent/BR112013010535A2/pt not_active Application Discontinuation
- 2011-10-27 JP JP2013536823A patent/JP6243737B2/ja active Active
-
2013
- 2013-04-26 MX MX2018007983A patent/MX2018007983A/es unknown
-
2015
- 2015-03-30 US US14/673,539 patent/US20160046701A1/en not_active Abandoned
-
2019
- 2019-01-24 US US16/256,800 patent/US20190352380A1/en not_active Abandoned
-
2021
- 2021-08-19 US US17/406,611 patent/US20210380671A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536109A5 (enExample) | ||
| US12371507B2 (en) | CDCP1 antibodies and antibody drug conjugates | |
| JP2013518912A5 (enExample) | ||
| BR112019025188A2 (pt) | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos | |
| EP3378873B1 (en) | Anti-claudin 1 monoclonal antibodies for the prevention and treatment of hepatocellular carcinoma | |
| RU2013123792A (ru) | Композиции, нацеленные на растворимый внеклеточный домен е-кадгерина, и связанные с ними способы лечения онкологических заболеваний | |
| JP2016509582A5 (enExample) | ||
| KR20170008202A (ko) | 흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체 | |
| JP2012100677A5 (enExample) | ||
| CN114207117A (zh) | 用于调节巨噬细胞活性的方法 | |
| JP7374765B2 (ja) | 抗ｄｋｋ－１抗体を使用して癌を治療するためのバイオマーカーとしてのベータ－カテニンの使用 | |
| JP2016520527A (ja) | 細胞表面ｇｒｐ７８に結合する抗体を使用したがんの処置 | |
| WO2018124009A1 (ja) | 低体温改善剤 | |
| CN114929275A (zh) | 使用dkk-1抑制剂治疗癌症的方法 | |
| US9914768B2 (en) | Anti-S100A7 antibodies for the treatment and diagnosis of cancer | |
| JP2015514062A5 (enExample) | ||
| KR102769405B1 (ko) | Igfbp-3 및 그것의 수용체와 관련되는 질환의 치료 | |
| CN103421112B (zh) | 一种抗肠道病毒的结合分子及其用途 | |
| JP7722989B2 (ja) | がんを治療するための方法及び組成物 | |
| Zhang et al. | Prophylactic efficacy of an intranasal spray with 2 synergetic antibodies neutralizing Omicron | |
| JP7357347B2 (ja) | 細胞外のＰＫＣδを標的とする肝癌細胞増殖抑制剤及びそれを含む新規肝癌治療薬 | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| HK40118760A (zh) | 特异性结合api5蛋白的抗体 | |
| JP2026511516A (ja) | Ａｐｉ５エピトープおよびそれに特異的に結合する抗体 | |
| WO2026082153A1 (zh) | 抗Nectin-4抗体药物偶联物治疗肿瘤的用途 |